CASI Pharmaceuticals, Inc.
CASIF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962738
No open-market purchases or sales by CASI Pharmaceuticals, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $17 in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding CASI Pharmaceuticals, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 22 | 23 | +1 |
| Shares | 2.66M | 2.74M | +86.2K (+3.2%) |
| Value | $7.52M | $5.93M | −$1.60M (−21.2%) |
New holders (3)
Institutions that held CASI Pharmaceuticals, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 21,143 | $45.7K | 0.00% |
| AdvisorNet Financial, Inc | 26 | $56 | 0.00% |
| Simplex Trading, LLC | 114 | $0 | 0.00% |
Sold out (2)
Institutions that held CASI Pharmaceuticals, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Trust Co of Vermont | 10 | $28 |
| Wingate Wealth Advisors, Inc. | 2 | $6 |